west
africa
ebov
epidem
biggest
ebov
outbreak
date
analysi
virusspecif
tcell
immun
survivor
show
individu
respons
least
one
ebov
protein
domin
respons
subject
specif
ebov
nucleocapsid
protein
np
suggest
epitop
ebov
np
could
form
import
part
effect
tcell
vaccin
ebola
zair
show
peptid
yqvnnleei
locat
conserv
region
ebov
np
provid
protect
morbid
mortal
mous
adapt
ebov
challeng
singl
vaccin
biorxiv
preprint
mous
use
adjuv
microspher
peptid
vaccin
formul
contain
enough
confer
immun
mice
work
suggest
peptid
vaccin
base
tcell
immun
ebov
survivor
conceptu
sound
feasibl
nucleocapsid
protein
within
contain
multipl
class
epitop
predict
hla
restrict
consist
broad
popul
coverag
similar
approach
ctl
vaccin
design
may
possibl
viru
ipvyqvnnleeicqliiqaf
also
suggest
ctl
vaccin
could
design
use
epitop
target
tcell
identifi
ebov
control
human
pathogenderiv
peptid
antigen
also
recogn
tcell
previous
describ
includ
peptid
vesicular
stomat
viru
vsv
rgyvyqgl
human
immunodefici
viru
hiv
rgpgrafvti
exist
epitop
make
rang
preclin
vaccin
experi
possibl
without
reli
nonhuman
pri
mate
expens
complextomanag
human
mous
model
wilson
et
al
show
ebov
nucleoprotein
np
immunogen
provid
protect
ctlmediat
immun
ebov
mous
model
protect
confer
peptid
sequenc
within
ebola
zair
vyqvnnleeic
wilson
et
al
came
conclus
base
studi
splenocyt
harvest
mice
vaccin
ebola
zair
np
use
venezuelan
equin
enceph
vee
vector
experi
show
splenocyt
vaccin
mice
restimul
fabric
adjuv
microspher
studi
room
temperatur
stabl
dri
powder
use
flow
focus
process
diamet
prevent
one
microspher
phagocytos
given
antigen
present
cell
apc
time
load
one
peptid
sequenc
per
microspher
maxim
peptid
payload
mitig
possibl
multipl
differ
peptid
sequenc
deliv
apc
simultan
could
possibl
result
competit
inhibit
motif
could
interfer
antigen
present
subsequ
tcell
expans
supplementari
materi
section
also
set
see
similar
approach
ctl
vaccin
design
would
feasibl
base
analysi
hla
bind
characterist
peptid
sequenc
nucleocapsid
use
previous
describ
biodegrad
dri
powder
plga
microspher
synthet
vaccin
platform
adjuv
agonist
studi
articl
show
agonist
given
togeth
peptid
mous
model
produc
tcell
expans
elispot
microencapsul
peptid
ligand
ligand
inject
solut
requir
elicit
immun
respons
deliv
peptid
antigen
determin
elispot
studi
also
demonstr
microencapsul
peptid
alon
insuffici
induc
adequ
immun
respons
without
presenc
agonist
administ
describ
tlr
agonist
use
vaccin
formul
use
fda
approv
vaccin
sourc
nongmp
gmp
materi
preclin
clinic
studi
show
b
restrict
epitop
vsv
rgyvyqgl
ova
siinfekl
administ
mice
produc
elispot
respons
administ
peptid
antigen
statist
signific
respons
measur
elispot
shown
figur
use
adjuv
microspher
peptid
vaccin
platform
immun
mice
ctl
class
peptid
antigen
ebola
ziar
np
protein
identifi
protect
wilson
et
al
microspher
contain
cpg
prepar
dri
powder
formul
suspend
use
pb
inject
solut
contain
mpla
administ
intraderm
via
inject
base
tail
mice
describ
previou
public
illustr
figur
statist
signific
differ
elispot
data
vaccin
mice
versu
respons
seen
neg
elispot
control
wilson
report
protect
seen
experi
due
peptid
sequenc
within
hypothes
epitop
ineffici
process
mhc
bind
subsequ
antigen
present
order
explor
possibl
b
match
peptid
sequenc
contain
within
ebola
zair
vyqvnnleeic
prepar
three
peptid
vaccin
formul
contain
one
three
possibl
subsequ
within
sequenc
shown
tabl
vaccin
via
intraderm
tail
inject
three
group
mice
microspher
contain
one
three
subsequ
per
group
elispot
analysi
perform
stimul
harvest
splenocyt
three
possibl
subsequ
splenocyt
mice
receiv
subsequ
statist
higher
elispot
respons
mice
vaccin
two
possibl
subsequ
p
shown
figur
consist
predict
b
bind
subsequ
vyqvnnleeic
peptid
predict
favor
b
bind
affin
shown
supplementari
materi
tabl
show
vaccin
mice
adjuv
microspher
vaccin
load
show
elispot
respons
wherea
mice
vaccin
adjuv
microspher
load
tide
figur
also
show
mice
vaccin
alon
show
elispot
respons
figur
convers
mice
vaccin
show
respons
figur
conduct
pilot
studi
demonstr
intraperiton
inject
adjuv
microspher
vaccin
produc
statist
superior
immun
peak
mortal
across
group
test
seen
mice
challeng
pfu
maebov
versu
pb
buffer
control
shown
surviv
curv
activ
vaccin
mice
expos
pfu
maebov
pb
buffer
mockvaccin
mice
show
mortal
increas
pfu
pfu
shown
figur
figur
saw
paradox
effect
control
anim
surviv
increas
figur
pfu
figur
believ
caus
innat
immun
trigger
larg
maebov
challeng
mice
vaccin
saw
appear
innat
immun
respons
pfu
ebov
exposur
level
suggest
ebov
mediat
innat
immun
respons
stimul
adjuv
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
microspher
vaccin
use
experi
incorpor
agonist
dose
mice
adjuv
microspher
without
peptid
found
level
protect
exposur
pfu
ebov
statist
differ
seen
pb
buffer
control
supplementari
materi
figur
conclud
level
protect
confer
adjuv
vaccin
describ
studi
depend
deliv
peptid
microspher
data
supplementari
materi
figur
also
show
two
separ
experi
conduct
month
apart
pfu
maebov
challeng
dose
activ
vaccin
formul
vaccin
anim
activ
group
surviv
morbid
clinic
observ
provid
evid
protect
effect
vaccin
use
adjuv
microspher
vaccin
reproduc
serum
sampl
sacrif
anim
expos
ebov
receiv
vaccin
quantit
assay
variou
cytokin
use
bioplex
plate
anim
unwit
demis
serum
sampl
collect
pearson
correl
analysi
perform
assess
relationship
specif
cytokin
level
surviv
result
shown
tabl
retriev
sequenc
process
use
multipl
sequenc
align
msa
via
clustal
nucleocapsid
phosphoprotein
nucleocapsid
phosphoprotein
sequenc
trim
everi
possibl
peptid
sequenc
amino
acid
length
chosen
typic
repres
subset
peptid
sequenc
present
sar
immunolog
epitop
databas
analysi
resourc
iedb
collect
previou
outbreak
predict
valu
peptid
cross
referenc
actual
invitro
bind
measur
ident
peptid
data
avail
prevent
vaccin
design
elicit
humor
immun
respons
typic
via
administr
whole
protein
pathogen
antibodi
vaccin
typic
produc
robust
tcell
respons
tcell
vaccin
meant
elicit
cellular
immun
respons
direct
cell
expand
attack
cell
present
hla
class
restrict
pathogenderiv
peptid
antigen
difficulti
obtain
reliabl
immun
respons
peptid
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
antigen
hla
restrict
natur
ctl
vaccin
limit
util
protect
individu
infecti
diseas
howev
observ
deriv
individu
abl
control
hiv
infect
ebov
infect
demonstr
control
may
associ
specif
ctl
target
behavior
suggest
may
import
role
hlarestrict
peptid
vaccin
protect
infecti
diseas
develop
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
match
class
ii
epitop
use
adjuv
microspher
peptid
vaccin
platform
protect
mortal
morbid
maebov
challeng
dose
test
mous
model
accomplish
adjuv
microspherebas
synthet
ctl
peptid
vaccin
platform
produc
protect
immun
respons
day
singl
administr
ebov
caus
sever
pulmonari
problem
expos
subject
problem
especi
sever
viru
deliv
aerosol
interact
ebov
specif
antibodi
nhp
lung
tissu
ebov
deliv
nhp
via
aerosol
produc
lethal
effect
nhp
without
circul
antiebov
antibodi
expos
aerosol
ebov
unpublish
tabl
taken
togeth
peptid
vaccin
base
yqvnnleei
vknevnsfkaalsslakhg
could
produc
cellular
immun
respons
popul
sudan
popul
north
america
intern
protein
locat
within
influenza
viru
contrast
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
coprotein
present
surfac
show
high
degre
conserv
epitop
within
intern
protein
often
stimul
tcellmedi
immun
respons
result
vaccin
stimul
influenza
specif
tcell
immun
consid
candid
univers
influenza
vaccin
proceed
determin
predict
hla
popul
coverag
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
addit
peptid
vaccin
mitig
risk
antibodi
diseas
enhanc
ade
seen
context
nonneutr
antibodi
respons
whole
protein
vaccin
also
neutral
antibodi
direct
spike
protein
patient
associ
increas
risk
acut
lung
injuri
ali
specif
patient
succumb
found
develop
neutral
antibodi
nab
respons
spike
protein
faster
survivor
onset
symptom
nab
titer
higher
patient
die
compar
recov
extent
antibodi
vaccin
produc
antibodi
respons
spike
protein
could
increas
risk
ali
risk
could
also
mitig
use
peptid
vaccin
altern
approach
extent
outbreak
allow
mani
control
anim
handl
done
accord
nih
institut
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
flow
pharma
inc
thoma
blicher
jett
sandholm
kastrup
soren
buu
michael
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
peptid
immun
respons
elispot
cell
popul
ns
signific
authorfund
right
reserv
reus
allow
without
permiss
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
surviv
curv
versu
pb
buffer
control
differ
number
survivor
vaccin
group
versu
pb
control
group
statist
signific
chi
squar
p
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
surviv
curv
versu
pb
buffer
control
differ
number
survivor
vaccin
group
versu
pb
control
group
statist
signific
chi
squar
p
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
